Market Rating: Is Horizon Pharma (HZNP) Worth Your Time After Citigroup’s Upgrade?

November 28, 2016 - By Marguerite Chambers

Market Rating:  Is Horizon Pharma (HZNP) Worth Your Time After Citigroup's Upgrade?

Horizon Pharma (HZNP) Upgrade

In a note revealed to clients today, Citigroup boosted shares of Horizon Pharma (HZNP) to a “Buy” rating from “Neutral” rating.

About 776,169 shares traded hands. Horizon Pharma PLC (HZNP) has risen 32.49% since April 25, 2016 and is uptrending. It has outperformed by 26.48% the S&P500.

Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on March, 6. They expect $0.52 EPS, 0.00% or $0.00 from last year’s $0.52 per share. HZNP’s profit will be $83.89M for 10.22 P/E if the $0.52 EPS becomes a reality. After $0.56 actual EPS reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.

Insitutional Activity: The institutional sentiment increased to 1.46 in 2016 Q2. Its up 0.25, from 1.21 in 2016Q1. The ratio is positive, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.

Brick Kyle Associate holds 0.01% or 400 shares in its portfolio. Voya Investment Mngmt Ltd Liability Corporation last reported 69,426 shares in the company. Barclays Public accumulated 294,248 shares or 0.01% of the stock. Lombard Odier Asset Management (Usa), a New York-based fund reported 350,000 shares. Bankshares Of Mellon accumulated 0% or 699,070 shares. Balyasny Asset Mgmt Ltd Llc accumulated 534,640 shares or 0.06% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 3,922 shares. Blackrock Institutional Tru Com Na has 0.01% invested in the company for 3.67M shares. Raymond James & Associates has 166,881 shares for 0.01% of their US portfolio. Qs Invsts Ltd has invested 0.01% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Moreover, D E Shaw And has 0.03% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 927,514 shares. Deerfield holds 8.89% or 13.74 million shares in its portfolio. Allianz Asset Management Ag accumulated 1.18M shares or 0.01% of the stock. Fiera Corporation reported 1.75 million shares or 0.16% of all its holdings. Brandywine Glob Mgmt Limited Co reported 2.81M shares or 0.31% of all its holdings.

Insider Transactions: Since June 15, 2016, the stock had 0 insider purchases, and 2 sales for $500,280 net activity. Shares for $58,000 were sold by SHERMAN JEFFREY W on Tuesday, August 2. Nohria Virinder sold $442,280 worth of stock.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The company has a market cap of $3.43 billion. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It currently has negative earnings. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”

HZNP Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.

More recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Fool.com which released: “Why Horizon Pharma PLC Jumped Higher Today” on November 07, 2016. Also Seekingalpha.com published the news titled: “Horizon Pharma Plc (HZNP) Q3 2016 Results – Earnings Call Transcript” on November 07, 2016. Globenewswire.com‘s news article titled: “Horizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate …” with publication date: November 03, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>